Fundz

Xenetic Biosciences, Inc. reported raising $252,000 in an initial SEC Form D filing, from an offering of $252,000

PUBLIC · XBIOJul 18, 2019

Amount Raised

$252,000

$252,000 sold, per SEC Form D (first sale Jul 18, 2019)

Round Type

Seed

FraminghamBiotechnology

Quick answer

Xenetic Biosciences raised $252,000 in a Seed round, dated July 18, 2019. Xenetic Biosciences is based in Framingham, Massachusetts, United States.

How much did Xenetic Biosciences raise?
Xenetic Biosciences raised $252,000 in a Seed round on July 18, 2019.
What does Xenetic Biosciences do?
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.
Where is Xenetic Biosciences based and how big is it?
Xenetic Biosciences is based in Framingham, Massachusetts, United States. Fundz records about 11 employees.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Xenetic Biosciences that raised within 45 days of this round, from Fundz verified event records.

Who to call at Xenetic Biosciences, and when

A new round usually means Xenetic Biosciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Xenetic Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Xenetic Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Xenetic Biosciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Xenetic Biosciences

Location

40 SPEEN STREET, SUITE 102

Framingham, Massachusetts, United States

About

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Xenetic Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Xenetic Biosciences's next move

See what Strategic adds

Xenetic Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.